MAD: Average Change from Baseline in Serum Iron Through Day 7 Figure 1 MAD: Average Change from Baseline in Transferrin...
Nes Ziona, Israel, Dec. 07, 2020 (GLOBE NEWSWIRE) -- Enlivex Therapeutics Ltd. (Nasdaq: ENLV, the “Company”), a clinical-stage immunotherapy company,...
Expanded data set supports efficacy across key measures including complete remission and MRD(-) rates, duration of response and overall survival...
-- Former Moderna executive and industry veteran brings diverse operational expertise as Oncorus plans buildout of its manufacturing capabilities to support...
KBP-5074 Achieves 10.1 mmHg reduction in systolic blood pressure (SBP) at 0.5mg dose compared to placebo Positive diastolic blood pressure...
SAN FRANCISCO, Dec. 07, 2020 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (“Olema” or “Olema Oncology”), a clinical-stage biopharmaceutical company focused...
NEW YORK, NY, REHOVAT, ISRAEL, SINGAPORE, Dec. 07, 2020 (GLOBE NEWSWIRE) -- via NewMediaWire --Todos Medical (OTCQB: TOMDF),an in vitro diagnostics company focused on...
HOUSTON, Dec. 07, 2020 (GLOBE NEWSWIRE) -- Bellicum Pharmaceuticals, Inc. (NASDAQ:BLCM), a leader in developing novel, controllable cellular immunotherapies for...
53.8% ORR in relapsed/refractory DLBCL patients Preliminary duration of response of up to 168 days observed, with six of seven...
Once-Weekly Twirla is the first and only contraceptive patch that combines levonorgestrel and ethinyl estradiol (EE) PRINCETON, N.J., Dec. 07,...
NEW YORK, Dec. 07, 2020 (GLOBE NEWSWIRE) -- Delcath Systems, Inc. (NASDAQ: DCTH), an interventional oncology company focused on the...
Data presented at the 62nd American Society of Hematology (ASH) Annual Meetingshow extremely favorable safety profile and clinical activity 89%...
Supplemental Analyses of GALACTIC-HF Left: Forest plot of the primary composite endpoint for subgroups of patients with lower left ventricular...
Topline results from the U.S. pivotal Phase 3 program anticipated in the fourth quarter of 2021Sofpironium bromide gel, 5% (ECCLOCK®)...
TORONTO, Dec. 07, 2020 (GLOBE NEWSWIRE) -- VitalHub Corp. (the “Company” or “VitalHub”) (TSXV: VHI) is pleased to announce that...
Leveraging NextGen® Population Health Solutions, Clinically Integrated Network Improves Quality of Patient Care While Exceeding Its Savings Objectives for Two...
LONDON--(BUSINESS WIRE)--$LIVN--LivaNova PLC (NASDAQ:LIVN), a market-leading medical technology and innovation company, today announced a series of enhancements to the Company’s...
VANCOUVER, BC / ACCESSWIRE / December 7, 2020 / Eyam Vaccines and Immunotherapeutics (EYAM) announced that a License Agreement has...
- ORRs of 73% and 77% with Belumosudil 200 mg QD and 200 mg BID, Respectively - - cGVHD Key...
67% spleen volume response rate observed in 63 first-line myelofibrosis patients treated with CPI-0610 + ruxolitinib at 24 weeksCPI-0610 demonstrated...